trolamine salicylate has been researched along with Hypertrophy, Left Ventricular in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hada, Y; Kakio, Y; Kojima, F; Morita, Y; Mukai, T; Otaka, N; Takeuchi, H; Uchida, HA; Wada, J; Yoshida, M | 1 |
| Fingleton, B | 1 |
1 review(s) available for trolamine salicylate and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Matrix metalloproteinases as valid clinical targets.
Topics: Animals; Arthritis; Atherosclerosis; Drug Design; Extracellular Matrix Proteins; Eye Diseases; Heart Rupture, Post-Infarction; Humans; Hypertrophy, Left Ventricular; Matrix Metalloproteinase Inhibitors; Matrix Metalloproteinases; Myocardial Infarction; Neoplasms; Protease Inhibitors; Pulmonary Disease, Chronic Obstructive; Respiratory Distress Syndrome; Skin Diseases; Stroke; Vascular Diseases | 2007 |
1 other study(ies) available for trolamine salicylate and Hypertrophy, Left Ventricular
| Article | Year |
|---|---|
Inhibition of interleukin-6 signaling attenuates aortitis, left ventricular hypertrophy and arthritis in interleukin-1 receptor antagonist deficient mice.
Topics: Animals; Antibodies; Aortitis; Arteries; Arthritis; Body Weight; Female; Hemodynamics; Hypertrophy, Left Ventricular; Immunity, Innate; Inflammation; Interleukin 1 Receptor Antagonist Protein; Interleukin-6; Male; Mice, Knockout; Organ Size; Signal Transduction; Sinus of Valsalva | 2020 |